NASDAQ | TSX: ACB
Largest Global Medical Cannabis Company
Operating in Nationally Regulated Markets, Aurora Removes
Concession Card Requirements to Access IndiMed Products in
Australia
EDMONTON, AB, Feb. 14,
2025 /CNW/ - Aurora Cannabis Inc.
(the "Company" or "Aurora") (NASDAQ: ACB)
(TSX: ACB), the Canadian-based leading global medical cannabis
company, in conjunction with MedReleaf Australia, recently removed
the concession card requirement for patients to access medical
cannabis products under the Company's IndiMed brand. By removing
this eligibility barrier, any patient in Australia can now be prescribed IndiMed
products, providing greater patient access to high quality medical
cannabis options.
![Aurora Logo (CNW Group/Aurora Cannabis Inc.) Aurora Logo (CNW Group/Aurora Cannabis Inc.)](https://mma.prnewswire.com/media/2620957/Aurora_Cannabis_Inc__Breaking_Down_Barriers__Aurora_Cannabis_Eas.jpg)
"This change to open up patient access to MedReleaf's
IndiMed products reflects our dedication to supporting prescribers
by creating more seamless and simplified prescribing options," said
Andre Jerome, Executive Vice
President, Global Business Development at Aurora. "It is a
testament to our unmatched expertise in navigating international
markets that we have the ability to quickly adapt and apply
necessary change with ease, in order to meet patient demand in the
rapidly growing medical cannabis market in Australia."
IndiMed was first launched in Australia in 2021 as the very first concession
product in the market. Over the years, the IndiMed portfolio has
expanded to include oil, additional dried flower product and resin
cartridges. Today, IndiMed flower product is consistently
ranked in the top 10 most prescribed flowers for cannabis
patients.
MedReleaf Australia, a wholly owned subsidiary of Aurora,
is committed to quality, consistency and proudly meets all TGA-GMP
standards. For further information about the company's offerings,
doctors and health care professionals can contact MedReleaf
Australia's clinical support team or visit their
website: www.medreleafaustralia.com.au.
In addition, the Company announced it has filed a final
short form base shelf prospectus with securities regulators in each
of the provinces of Canada, except Quebec, and a
corresponding shelf registration statement on Form F–10 with the
United States Securities and Exchange Commission.
This news release does not constitute an offer of any securities
for sale.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the
medical and consumer markets across Canada, Europe, Australia and South
America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis, dedicated to helping people improve their lives.
The Company's adult-use brand portfolio includes Drift, San Rafael
'71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis
brands include MedReleaf, CanniMed, Aurora and Whistler Medical
Marijuana Co., as well as international brands, Pedanios, IndiMed
and CraftPlant. Aurora also has a controlling interest in Bevo
Farms Ltd., North America's
leading supplier of propagated agricultural plants. Driven by
science and innovation, and with a focus on high-quality cannabis
products, Aurora's brands continue to break through as industry
leaders in the medical, wellness and adult recreational markets
wherever they are launched. Learn more at
www.auroramj.com and follow us on X
and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the
symbol "ACB".
Forward Looking Information:
This news release includes statements
containing certain "forward-looking information" within the meaning
of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include, but are not limited
to, statements regarding the removal of the concession card
requirement for patients to access medical cannabis products under
the Company's IndiMed brand and the associated impact on the access
to products for patients in Australia, as well statements regarding
expectations for the growth of the Australian medical cannabis
market.
These forward-looking statements are only predictions. Forward
looking information or statements contained in this news release
have been developed based on assumptions management considers to be
reasonable. Material factors or assumptions involved in developing
forward-looking statements include, without limitation, publicly
available information from governmental sources as well as from
market research and industry analysis and on assumptions based on
data and knowledge of this industry which the Company believes to
be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes
to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements. These risks include,
but are not limited to, the ability to retain key personnel, the
ability to continue investing in infrastructure to support growth,
the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the
development of third party government and non-government consumer
sales channels, management's estimates of consumer demand in
Canada and in jurisdictions where
the Company exports, expectations of future results and expenses,
the risk of successful integration of acquired business and
operations (with respect to the Transaction and more generally with
respect to future acquisitions), management's estimation that
SG&A will grow only in proportion of revenue growth, the
ability to expand and maintain distribution capabilities, the
impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product
demand, changes in prices of required commodities, competition, and
the possibility for changes in laws, rules, and regulations in the
industry, epidemics, pandemics or other public health crises and
other risks, uncertainties and factors set out under the heading
"Risk Factors" in the Company's annual information from dated
June 20, 2024 (the "AIF") and filed
with Canadian securities regulators available on the Company's
issuer profile on SEDAR+ at www.sedarplus.com and filed with and
available on the SEC's website at www.sec.gov. The Company cautions
that the list of risks, uncertainties and other factors described
in the AIF is not exhaustive and other factors could also adversely
affect its results. Readers are urged to consider the risks,
uncertainties and assumptions carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable securities law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/breaking-down-barriers-aurora-cannabis-eases-patient-access-to-high-quality-medical-cannabis-products-in-australia-302377404.html
SOURCE Aurora Cannabis Inc.